Quick answer: topical and oral interventions solve different delivery problems. Topicals act at or through the skin barrier; oral compounds must survive digestion, absorption, metabolism and systemic distribution. Neither route is automatically superior. The correct question is whether a particular intervention reaches its target and improves a meaningful outcome in human studies.
Key takeaways
- Topical does not mean superficial: sunscreens, retinoids and other topical interventions can produce meaningful human outcomes.
- Oral does not automatically mean deeper: systemic delivery introduces absorption, metabolism and tissue-distribution constraints.
- The 500 Dalton rule is a formulation heuristic: it does not prove that creams fail or that supplements reach the dermis effectively.
- Clinical outcomes settle route debates: a route is useful when a specific intervention demonstrates the intended result.
The old “creams don't work” argument is wrong
Some topical ingredients primarily hydrate or protect the surface. Others penetrate enough to influence living skin. Most importantly, clinical outcomes settle the debate: regular sunscreen has randomized human evidence for slowing photoaging, and topical tretinoin has randomized-trial evidence for improving photoaged skin.
Sunscreen randomized trial · Tretinoin systematic review
What topicals are especially good at
- Photoprotection: sunscreens reduce UV exposure at the skin surface.
- Barrier support: moisturizers reduce water loss and improve dryness.
- Local active delivery: appropriately formulated small molecules such as retinoids can affect epidermal and dermal processes.
- Targeted treatment: dermatology uses topical drugs precisely because local delivery can be effective.
The 500 Dalton rule is not a verdict on skincare
Molecular weight is an important determinant of passive skin penetration, and a classic paper proposed roughly 500 Da as a practical threshold. But molecular size is not the only factor, and an ingredient can provide a valid surface benefit without reaching the dermis.
For the full explanation—including collagen, hyaluronic acid and why oral delivery creates different pharmacokinetic questions—read The 500 Dalton Rule: What It Really Means for Skincare.
What oral delivery is especially good at
Oral delivery can expose the body systemically to nutrients, drugs and metabolites after absorption. This makes sense for targets that are not accessible through skin. But systemic delivery brings its own limitations: first-pass metabolism, low bioavailability, interactions, variable blood levels and uncertain tissue concentrations.
“It reaches the bloodstream” is not enough
A molecule appearing in blood does not prove it reaches dermal fibroblasts at an effective concentration. Likewise, a biomarker change does not prove a visible skin benefit. Finished-product studies remain the strongest way to connect a route with an outcome.
Compare the evidence question, not the marketing story
| Route | Main delivery question | What counts as strong evidence? |
|---|---|---|
| Topical | Can the formulation reach or affect the intended skin target? | Controlled human outcomes with the relevant topical formulation. |
| Oral | Is the ingredient absorbed, metabolized and distributed to relevant tissue? | Human pharmacokinetic/biomarker data plus controlled clinical outcomes. |
| Either | Does the intervention improve a meaningful endpoint? | Trials measuring the endpoint rather than assuming it from mechanism. |
Where oral collagen fits
Collagen peptides have multiple randomized skin studies, although recent meta-analysis raises questions about quality and funding bias. Their evidence is more direct for visible skin endpoints than the current evidence for direct oral NAD+.
See Collagen vs NAD+ for the evidence comparison.
Where NAD+, quercetin and resveratrol fit
NAD biology, cellular senescence and polyphenol signaling are important research areas. Yet PAG NAD CORE has not been clinically shown to outperform established topical interventions or to reverse wrinkles. PAG LABS treats the formula as an adjunctive dietary-supplement approach, not a replacement for sunscreen, moisturization or medical dermatology.
An evidence-first combined framework
- Protect: reduce cumulative UV damage.
- Maintain: support barrier function and address dryness.
- Treat: use validated topical or clinical interventions when appropriate.
- Support systemic health: adequate nutrition, exercise, sleep and smoking avoidance.
- Evaluate supplements separately: require human evidence appropriate to the molecule, dose and outcome.
FAQ
Are oral supplements better than creams for skin aging?
Not as a category. Each intervention has to be judged on delivery, dose and human outcomes. Some topical interventions have stronger direct photoaging evidence than many oral supplements.
Do ingredients have to be under 500 Daltons to work on skin?
No. The rule concerns passive penetration through intact skin and is not a universal efficacy cutoff. Surface hydration or protection can be useful without dermal penetration, and formulation matters.
Does entering the bloodstream prove an oral ingredient reaches skin?
No. Blood exposure is one step; tissue distribution and effective concentration at the target still need to be established.
Can an oral supplement replace sunscreen?
Current evidence does not support that substitution. Photoprotection directly reduces a major environmental driver of photoaging.
Bottom line
The future of skin longevity is unlikely to be “topical or oral.” It is more likely to be a layered strategy in which each intervention earns its place through evidence. Route of administration is a pharmacology question—not a marketing hierarchy.
Related PAG LABS research
Last reviewed: September 2026.
Educational content only; not medical advice.